Blocking PD-1/PD-L1/2 way — promising treatment strategy of patients with B-cell lymphomas (review)
Kriachok I.A., Novosad I.O., Khranovskaya N.M., Svеrgun N.N., Filonenko K.S., Stepanishyna Y.A., Titorenko I.B., Kadnikova T., Skripets Т.V.
Summary. Immunotherapeutic approaches to treating cancer have been evaluated during the last few decades with limited success. An understanding of the checkpoint signaling pathway involving the programmed death 1 (PD-1) receptor and its ligands (PD-L1/2) has clarified the role of these approaches in tumor-induced immune suppression and has been a critical advancement in immunotherapeutic drug development.
Leave a comment